A comprehensive review has been published on novel immunotherapeutic strategies for diffuse large B-cell lymphoma. The review appears to cover various treatment options, including the use of bispecific antibodies and chimeric antigen receptor t-cell therapy, as well as targeting specific vulnerabilities such as metabolic ones. Different outlets are highlighting different aspects of the review, including comparisons of treatment efficacy and discussions of overcoming immunotherapy resistance.